Extranodal Natural-Killer/T-Cell Lymphoma, Nasal Type
Author Information
Author(s): Harinder Gill, Raymond H. S. Liang, Eric Tse
Primary Institution: University of Hong Kong, Queen Mary Hospital
Conclusion
The prognosis for nasal NK/T-cell lymphomas has improved with modern treatment protocols, but remains guarded for extranasal and disseminated cases.
Supporting Evidence
- Nasal NK/T-cell lymphomas account for 7% to 10% of all non-Hodgkin lymphomas in Asia and Latin America.
- Patients with IPI of 1 or less have better overall survival.
- High levels of circulating plasma EBV DNA correlate with high tumor load and poorer response to treatment.
- Combination of chemotherapy and radiotherapy is the current standard of care for patients who can tolerate systemic treatment.
Takeaway
This study talks about a type of cancer that affects certain immune cells and how it is treated, especially in different parts of the body.
Methodology
The study reviews existing literature and treatment protocols for NK/T-cell lymphoma.
Limitations
The study lacks randomized control trials due to the low incidence of NK/T-cell malignancies.
Participant Demographics
Most cases reported are in males, typically in their fifties, with a distinctive geographical distribution in Asia and Latin America.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website